

Applicant: James W. Halbrook *et al.*
Serial No.: 10/550,978
Confirmation No.: 1639
Title: XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-
PK INHIBITORS
Filing Date: December 11, 2006
Examiner: Rebecca L. Anderson
Art Unit: 1626

CERTIFICATE OF ELECTRONIC FILING UNDER 37 C.F.R. § 1.8

The undersigned hereby certifies that this paper, along with any paper referred to as being attached or enclosed, is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4), on:

Dated: November 29, 2010

Electronic Signature for: /Eileen M. MacKenzie/

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement, pursuant to 37 CFR § 1.114(c), accompanies the Request for Continued Examination (37 CFR § 1.114) submitted herewith. No fee is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The above-identified U.S. application claims priority to Application Serial No. PCT/US2004/008459. If the Examiner has not had the benefit of review of the file history of PCT/US2004/008459, then he/she is asked to contact the undersigned, who will provide a copy of the same.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 10/550,978
Conf. No.: 1639

- 3 -

Art Unit: 1626

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

The Director is hereby authorized to charge any deficiency or credit any overpayment in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 23/2825 under Docket No. N0260.70068US01 from which the undersigned is authorized to draw.

Respectfully submitted,
Halbrook et al., Applicant

By: _____/Kevin M. Henry/_____
Kevin M. Henry, Reg. No. 65,647
Roque El-Hayek, Reg. No. 55,151
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: N0260.70068US01
Dated: November 29, 2010
xNDDx